Camille Mailho, Benoit Peyronnet, Marianne De Seze, Alexia Even, Maire-Aimée Perrouin-Verbe, Gérard Amarenco, Emmanuel Chartier-Kastler, Loic Le Normand, Andrea Manunta, Gilles Karsenty, Jacques Kerdraon, Alain Ruffion, Christian Saussine, Frédérique Le Breton, Benjamin Bernuz, Evelyne Castel-Lacanal, Pierre Denys, Véronique Phé, Xavier Gamé
INTRODUCTION: Neurogenic detrusor overactivity (NDO) has a major impact on patients' quality of life and can lead to upper urinary tract complications. Intradetrusor botulinum toxin type A injections are administered as second-line treatment to these patients following the failure of anticholinergic agents. The aim of the DETOX 2 study is to propose a consensus definition of the failure of intradetrusor botulinum toxin injections for NDO in patients presenting spinal cord injury, spina bifida, or multiple sclerosis (MS) with self-catheterization...
March 7, 2024: Neurourology and Urodynamics